prenylation. Our proof-of-concept screen lays the foundation for truly high-throughput screens that could help lead to the 24 development of clinically useful adjuvants that can one day be co-administered with statins.
reports, 12À15 The suppression of statin-induced toxicity in muscle cells by G€ o6976 is eliminated by inhibition of GGT-II. C2C12 myotubes were treated for 48 h with DMSO or 10 μM simvastatin in the presence of 10 μM GGPP, 5 μM G€ o6976, or 5 μM G€ o6976 with 10 μM BMS3 as indicated. ATP levels were normalized to the vehicle control. *, p < 0.01 (t test) relative to statin treatment; **, p < 0.01 (t test) relative to statin + G€ o6976 treatment. (e) Zebrafish embryos were treated for 12 h with combinations of 1 or 5 μM lovastatin and 10 μM G€ o6976. Embryos were fixed and stained for myosin heavy chain (see Methods) for muscle fiber size determination (red arrows). Representative somite phenotypes are shown, using 1 μM lovastatin; anterior, left. (f) Quantification of muscle fiber diameter, using 100 embryos per group. Results are graphed as the ratio of the mean experimental fiber size to the control fiber size. 
